Showing results (1-10 of 97) with videos related to
Sort By:
Pageof 10
Molecular Oncology|June 15, 2025
Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockadeTullia C Bruno, Anthony R CilloMethods in Molecular Biology (Clifton, N.J.)|November 11, 2024
An Introduction to Tertiary Lymphoid Structures in CancerHye Mi Kim, Tullia C BrunoFrontiers in Oncology|March 6, 2020
Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical ImplicationsTanner Smida, Tullia C Bruno, Laura P StabileJournal for Immunotherapy of Cancer|April 17, 2025
Past failures and new horizons: the nuances of tertiary lymphoid structures in high-grade serous ovarian cancer may contribute to immunotherapy effectivenessRufiaat Rashid, Lan Coffman, Tullia C Bruno, et al.Surgical Oncology Clinics of North America|March 28, 2026
B-cell-directed Immunotherapy for Solid TumorsRenee R Anderko, Adam Tcharni, Amer H Zureikat, et al.Trends in Cancer|July 19, 2022
Therapeutic targeting of regulatory T cells in cancerFeng Shan, Ashwin Somasundaram, Tullia C Bruno, et al.Journal for Immunotherapy of Cancer|July 18, 2020
Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapyChristopher A Chuckran, Chang Liu, Tullia C Bruno, et al.Seminars in Immunology|October 13, 2019
Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptorElisa Ruffo, Richard C Wu, Tullia C Bruno, et al.Nature Reviews. Cancer|December 1, 2022
Improving head and neck cancer therapies by immunomodulation of the tumour microenvironmentAyana T Ruffin, Housaiyin Li, Lazar Vujanovic, et al.Journal of Immunology (Baltimore, Md. : 1950)|July 3, 2016
Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer ModelKatherine A Waugh, Sonia M Leach, Brandon L Moore, et al.Pageof 10